Ratings by Rothschild Redburn (Jamie Clark)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/8/2026 | Tempus AI Inc | TEM | New Coverage | Neutral (N/A) |
64.66 (68.13) |
5.37% | Details | |
| 9/8/2026 | Natera | NTRA | New Coverage | Buy (N/A) |
327.67 (417.54) |
27.43% | Details | |
| 9/8/2026 | Guardant Health | GH | New Coverage | Buy (N/A) |
161.04 (168.79) |
4.81% | Details | |
| 2/17/2026 | ICON plc | ICLR | Downgrade | Neutral (Buy) |
80.08 (183.94) |
129.7% | Details | |
| 11/21/2025 | Certara Inc. | CERT | New Coverage | Buy (N/A) |
8.29 (10.07) |
21.47% | Details | |
| 9/15/2025 | West Pharmaceutical | WST | New Coverage | Buy (N/A) |
263.74 (394.80) |
49.69% | Details | |
| 9/3/2025 | Iconix Brand | ICON | Upgrade | Buy (Neutral) |
1.92 (0.95) |
-50.52% | Details | |
| 9/3/2025 | Medpace | MEDP | Downgrade | Neutral (Buy) |
475.51 (649.89) |
36.67% | Details | |
| 9/3/2025 | ICON plc | ICLR | Upgrade | Buy (Neutral) |
177.94 (80.08) |
-55% | Details | |
| 5/23/2025 | Charles River Labs | CRL | Upgrade | Buy (Neutral) |
134.98 (333.03) |
146.73% | Details | |
| 4/2/2025 | Quest Diagnostics | DGX | New Coverage | Buy (N/A) |
169.20 (237.85) |
40.57% | Details | |
| 4/2/2025 | Laboratory Corporation of America | LH | New Coverage | Buy (N/A) |
232.74 (322.90) |
38.74% | Details | |
| 3/3/2025 | Charles River Labs | CRL | Upgrade | Neutral (Sell) |
164.88 (134.98) |
-18.13% | Details |
